Loading...
Market
Story
Johnson & Johnson's Rybrevant Approved by FDA as Second-Line Treatment for EGFR-Mutated Advanced Lung Cancer
Sep 20, 2024, 12:12 PM
Johnson & Johnson's Rybrevant (amivantamab-vmjw) plus standard of care has received FDA approval for use as a second-line treatment for EGFR-mutated advanced lung cancer (NSCLC). This approval marks a significant milestone in oncology as it is the first targeted regimen to reduce the risk of disease progression by more than half. Johnson & Johnson aims to achieve $5 billion in sales for Rybrevant.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%